Keiji Wakabayashi Selected Research

Cyclooxygenase 2 (Cyclooxygenase-2)

5/2017	Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors.
2/2011	Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease.
3/2008	Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: the Self Defense Forces Health Study.
1/2006	Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms.
1/2005	Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase.
4/2004	Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
3/2002	Suppression of promoter-dependent transcriptional activity of inducible nitric oxide synthase by sodium butyrate in colon cancer cells.
1/2002	Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keiji Wakabayashi Research Topics

Disease

61	Carcinogenesis 12/2023 - 01/2002
59	Neoplasms (Cancer) 12/2023 - 01/2000
22	Colonic Neoplasms (Colon Cancer) 08/2017 - 01/2002
19	Adenocarcinoma 01/2022 - 04/2003
18	Colorectal Neoplasms (Colorectal Cancer) 02/2023 - 03/2006
18	Intestinal Polyps 01/2019 - 09/2002
16	Polyps 01/2022 - 09/2002
12	Inflammation (Inflammations) 12/2023 - 01/2000
11	Adenoma (Adenomas) 01/2022 - 06/2004
10	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2022 - 07/2003
9	Aberrant Crypt Foci 08/2017 - 01/2002
9	Hyperlipidemias (Hyperlipidemia) 02/2011 - 09/2003
8	Carcinoma (Carcinomatosis) 01/2021 - 01/2003
8	Body Weight (Weight, Body) 01/2014 - 06/2005
6	Pancreatic Neoplasms (Pancreatic Cancer) 05/2012 - 08/2007
4	Asthma (Bronchial Asthma) 01/2020 - 08/2018
4	Obesity 01/2016 - 08/2011
4	Gastritis 09/2013 - 02/2002
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2009 - 03/2006
3	Colitis 08/2007 - 01/2006
2	Stomach Neoplasms (Stomach Cancer) 02/2022 - 01/2012
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 01/2020
2	Allergic Rhinitis 01/2020 - 01/2020
2	Hypertriglyceridemia 01/2016 - 04/2008
2	Breast Neoplasms (Breast Cancer) 01/2016 - 01/2002
2	Ulcer 02/2013 - 06/2011
2	Infections 01/2012 - 02/2003
2	Lung Neoplasms (Lung Cancer) 09/2009 - 02/2008

Drug/Important Bio-Agent (IBA)

16	AzoxymethaneIBA 08/2017 - 01/2002
12	Messenger RNA (mRNA)IBA 05/2017 - 01/2002
11	CarcinogensIBA 02/2020 - 01/2002
11	ProstaglandinsIBA 03/2008 - 01/2000
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2002
10	LipidsIBA 11/2011 - 03/2003
9	Triglycerides (Triacylglycerol)IBA 01/2012 - 09/2003
8	colibactinIBA 02/2023 - 01/2019
8	DNA AdductsIBA 01/2021 - 01/2003
8	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2017 - 01/2002
8	Drinking WaterIBA 01/2014 - 10/2003
8	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2011 - 03/2002
7	EnzymesIBA 01/2022 - 01/2000
7	Dextrans (Dextran)FDA Link 01/2014 - 01/2005
7	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2014 - 01/2005
7	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 03/2008 - 01/2000
7	beta CateninIBA 10/2007 - 06/2004
7	Prostaglandins EIBA 03/2007 - 01/2002
6	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2023 - 02/2013
6	MutagensIBA 02/2023 - 04/2004
6	AminesIBA 01/2022 - 10/2007
6	nitrosobis(2-oxopropyl)amine (NBOP)IBA 05/2012 - 04/2003
6	PPAR gammaIBA 01/2012 - 09/2003
6	Pioglitazone (Actos)FDA Link 01/2012 - 09/2003
6	nimesulide (Aulin)IBA 03/2006 - 01/2002
6	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2006 - 01/2002
5	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 02/2020 - 01/2002
5	LigandsIBA 01/2012 - 09/2003
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2012 - 09/2003
5	AdipokinesIBA 01/2012 - 04/2008
4	QuinoxalinesIBA 02/2020 - 02/2008
4	EndotoxinsIBA 01/2020 - 08/2018
4	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 11/2004
4	PPAR alphaIBA 10/2007 - 09/2003
3	CateninsIBA 12/2023 - 01/2014
3	2-toluidine (o-toluidine)IBA 12/2020 - 01/2020
3	benzocycloheptapyridineIBA 02/2020 - 01/2005
3	LeptinIBA 01/2016 - 08/2011
3	Indomethacin (Indometacin)FDA LinkGeneric 11/2012 - 04/2004
3	Urethane (Ethyl Carbamate)IBA 11/2012 - 02/2008
3	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 12/2009 - 02/2005
3	7- chloro- 3- imino- 5- methyl- 2- azabicyclo(4.1.0)heptaneIBA 08/2008 - 03/2006
3	Protein Isoforms (Isoforms)IBA 03/2008 - 01/2000
3	Codon (Codons)IBA 02/2008 - 06/2004
3	Dinoprostone (PGE2)FDA Link 03/2007 - 05/2003
3	ONO 8711IBA 03/2007 - 07/2003
3	mofezolacIBA 10/2006 - 09/2002
3	Cyclooxygenase 1IBA 10/2006 - 09/2002
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2006 - 10/2003
3	Bromodeoxyuridine (BrdU)IBA 05/2005 - 09/2002
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2003 - 01/2002
2	PolyketidesIBA 01/2022 - 01/2020
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	AcetyltransferasesIBA 01/2021 - 01/2020
2	Mesalamine (Mesalazine)FDA LinkGeneric 01/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 03/2006
2	PowdersIBA 05/2020 - 06/2011
2	aniline (aniline hydrobromide)IBA 02/2020 - 03/2002
2	Particulate MatterIBA 01/2020 - 01/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2017 - 02/2008
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 08/2017 - 05/2017
2	Interleukin-6 (Interleukin 6)IBA 05/2017 - 02/2016
2	CytokinesIBA 01/2016 - 06/2011
2	Insulin (Novolin)FDA Link 01/2016 - 01/2012
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2016 - 01/2000
2	AcidsIBA 05/2012 - 09/2008
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2011 - 04/2008
2	DiglyceridesIBA 03/2009 - 06/2007

Therapy/Procedure

9	Chemoprevention 12/2021 - 07/2003
3	Colectomy 01/2021 - 01/2016
2	Intraperitoneal Injections 11/2012 - 06/2011
2	Injections 06/2011 - 05/2003